Cannabis Science Releases New Photos on the Continual Improvement of Patient Three Who Suffers from Squamous Cell Carcinoma
Dr. Robert J. Melamede, 1-888-889-0888President & CEOorRobert Kane, 1-561-234-6929VP Investor Relations
Cannabis Science (OTCBB:CBIS), a pioneering U.S. Biotech Company developing pharmaceutical products for global public health challenges is pleased to report on the continued progress made by Patient Three who suffers from an extremely severe case of chemo- and radiation-resistant squamous cell carcinoma.
Cannabis Science has been working closely with Patient Three for some time. He has been self-administering a topical cannabis-based extract, and continues to see reduction of the tumor mass along with apparent healing. The patient's oncologist is impressed with the improvement made from the topical application of CSSC-1.
The treatment has reduced the tumor mass down to the exposed skull, as seen in the lesion on the left side of the patient’s head. There has also been a significant reduction of the tumor mass on the right side of the patient’s head, and the outer perimeter of the tumor itself is decreasing. The growth of new tissue is readily seen.
An HIV physician with extensive oncology experience had the opportunity to view the photo-documentation from Patient 3 and commented, “How come I know nothing about this? We need to do trials now.”
Dr. Melamede however has noted that the healing process is taking longer now that the tumor has been significantly reduced in size. "Perhaps now that the tumor burden has been significantly reduced, surgery to close the wound might be a sensible option. We look forward hearing his oncologist's opinion after his next visit in August."
The new photos of Patent 3 can be seen on the Cannabis Science website , “View Images of 3rd Self-Medicated Patient & His Apparent Success.” More news on this 3rd patient, as well the other patients can be viewed on the Cannabis Science website, by clicking on the breaking news button where you will find all the cancer related and updated patient news.
Cannabis Science, Inc. is conducting cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products.
Cannabis Science is currently working with CBR International to develop a Pre-IND Application to the FDA that focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas.
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as “anticipate,” “seek,” intend,” “believe,” “plan,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements.